Propanc Biopharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Propanc Biopharma, Inc., a Delaware corporation with principal executive offices in Camberwell, Australia, filed this Current Report on Form 8-K on March 11, 2024, covering events occurring on March 5, 2024. The filing details the entry into a material definitive agreement involving the issuance of a convertible promissory note.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The specific financial transaction reported is as follows:
- Instrument: Convertible Promissory Note.
- Principal Amount: $50,000.
- Purchase Price: $46,875.
- Interest Rate: 8% per annum (increases to 16% upon default).
- Use of Proceeds: General working capital.
- Liquidity Impact: Immediate cash inflow of $46,875.
Material Changes and Transaction Terms
The Company entered into a Securities Purchase Agreement with an investor. Key terms of the Note include:
- Conversion: Convertible at the investor's option into common stock at 65% of the lowest closing trade price during the 10 trading days prior to conversion (35% discount).
- Ownership Limit: Conversions are subject to a 4.99% beneficial ownership limitation.
- Reserve Requirement: The Company must maintain a reserve of at least 500% of the number of Conversion Shares.
- Maturity Date: The text states the maturity date is March 1, 2024, which precedes the issuance date of March 5, 2024. This appears to be a clerical error in the source text; the filing does not provide a clear corrected maturity date.
- Prepayment: The Company has the right to prepay with premiums ranging from 110% to 125% of the face amount plus accrued interest, depending on the timing within the first 180 days. No prepayment right exists after 180 days.
Outlook, Risks, and Contingencies
The Note contains several events of default that would make the instrument immediately due and payable, including:
- Failure to pay principal or interest when due.
- Failure to timely issue Conversion Shares.
- Failure to maintain listing on an OTC market or equivalent exchange.
- Failure to comply with SEC reporting requirements.
- Insolvency, bankruptcy, or liquidation.
The issuance was made pursuant to the private placement exemption under Section 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the corrected maturity date of the Note, as the reported date (March 1, 2024) conflicts with the issuance date (March 5, 2024).
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Convertible Promissory Note (Exhibit 4.1) for complete terms.
- Assess the Company's ability to maintain the required 500% share reserve for potential conversion.
- Monitor the Company's compliance with OTC listing requirements and SEC reporting obligations to avoid default triggers.
- Confirm the identity of the investor and any related party status not explicitly detailed in the summary.